Psychotropic drugs, cardiac arrhythmia, and sudden death

Journal of Clinical Psychopharmacology

Volumn 23, Issue 1, 2003, Pages 58-77

  Witchel, Harry J ^a   Hancox, Jules C ^a   Nutt, David J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; CALCIUM ION; CARBAMAZEPINE; CHLORAL HYDRATE; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DESIPRAMINE; DOXEPIN; DROPERIDOL; ERYTHROMYCIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; MAPROTILINE; POTASSIUM CHANNEL; POTASSIUM ION; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SODIUM ION; TAMOXIFEN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ARRHYTHMOGENESIS; DISEASE PREDISPOSITION; DRUG METABOLISM; DRUG SAFETY; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; PATHOPHYSIOLOGY; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; REVIEW; SODIUM CURRENT; SUDDEN DEATH; TORSADE DES POINTES; VAGUS NERVE;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; ARRHYTHMIA; CELLS; DEATH, SUDDEN; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; ION CHANNELS; LONG QT SYNDROME; PSYCHOTROPIC DRUGS;

EID: 0037309586     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200302000-00010     Document Type: Review

References (237)

1. Sacks MH, Bonforte RJ, Laser RP, Dimich I. Cardiovascular complications of imipramine intoxication. JAMA 1968;205:588-590.
2. Kelly HG, Fay JE, Lavery SG. Thioridazine hydrochloride (Mellaril): its effects on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 1963;89:546-554.
3. Mehta D, Mehta S, Petit J, Shriner W. Cardiac arrhythmia and haloperidol. Am J Psychiatry 1979;136:1468-1469.
4. Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ. Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 1995;309:315-316.
5. Poole JE, Bardy GH. Sudden Cardiac Death. In: Zipes DP, Jalife J, eds. Cardiac Electrophysiology: from Cell to Bedside. London: W.B. Saunders Company, 2000:615-40.
6. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SH. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000;355:1048-1052.
7. Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent GM. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996;94:1996-2012.
8. Isacsson G, Bergman U. Risks with citalopram in perspective. Lancet 1996;348:1033.
9. Henry, JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Safety 1997;16:374-390.
10. Crumb W, Cavero I. QT interval prolongation by non- cardiovascular drugs: issues and solutions for novel drug development. Pharm Sci Technol Today 1999;2:270-280.
11. Committee for Proprietary Medicinal Products. Points to consider: the assessment for the potential for QT prolongation by non-cardiovascular medicinal products. Report # CPMP/986/96. London: European Agency for the Evaluation of Medicinal Products, 1997.
12. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991,84:1516-1523.
13. Benhorin J, Medina A. Images in clinical medicine. Congenital long-QT syndrome. N Engl J Med 1997;336:1568.
14. Witchel HJ, Hancox JC. Familial and acquired Long QT Syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharm Physiol 2000;27:753-766.
15. Chen SA, Chen YJ. Proarrhythmic activity and interactions of noncardiac drugs and other substances. Cardiac Electrophysiology Review 1998;2:147-150.
16. Moir DC, Cornwell WB, Dingwall-Fordyce I, Crooks J, O'Malley K, Turnbull MJ, Weir RD. Cardiotoxicity of amitriptyline. Lancet 1972;2:561-564.
17. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Brit J Pharmacol 1999;128:479-485.
18. Jo SH, Youm JB, Lee CO, Earm YE, Ho WK. Blockade of the HERG human cardiac K(+) channel by the antidepressant drug amitriptyline. Br J Pharmacol 2000;129:1474-1480.
19. Tie H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ. The heart of psychotropic drug therapy. Lancet 2000;355:1825.
20. Munger MA, Effron BA. Amoxapine cardiotoxicity. Ann Emerg Med 1988;17:274-278.
21. Iwahashi K. Significantly higher plasma haloperidol level during cotreatment with carbamazepine may herald cardiac change. Clin Neuropharmacol 1996;19:267-270.
22. Kenneback G, Bergfeldt L, Vallin H, Tomson T, Edhag O. Electrophysiologic effects and clinical hazards of carbamazepine treatment for neurologic disorders in patients with abnormalities of the cardiac conduction system. Am Heart J 1991;121:1421-1429.
23. Fetu D, Carel N, Fossier T, Motreff C. Chloral hydrate poisoning. Ann Fr Anesth Reanim 1994;13:745-748.
24. Warner JP, Barnes TR, Henry JA. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand 1996;93:311-313.
25. Personne M, Sjoberg G, Persson H. Citalopram overdose-review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35: 237-240.
26. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, Hancox JC. Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002;512:59-66.
27. Leonard HL, Meyer MC, Swedo SE, Richter D, Hamburger SD, Allen AJ, Rapoport JL, Tucker E. Electrocardiographic changes during desipramine and clomipramine treatment in children and adolescents. J Am Acad Child Adolesc Psychiatry 1995;34:1460-1468.
28. Hoehns JD, Fouts MM, Kelly MW, Tu KB. Sudden cardiac death with clozapine and sertraline combination. Ann Pharmacother 2001; 35:862-866.
29. Baker B, Dorian P, Sandor P, Shapiro C, Schell C, Mitchell J, Irvine MJ. Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J Clin Psychopharmacol 1997; 17:15-21.
30. Lischke V, Behne M, Doelken P, Schledt U, Probst S, Vettermann J. Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 1994;79:983-986.
31. Drolet B, Zhang S, Deschenes D, Rail J, Nadeau S, Zhou Z, January CT, Turgeon J. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999;10:1597-1604.
32. Michalets EL, Smith LK, Van Tassel ED. Torsade de pointes resulting from the addition of droperidol to an existing cytochrome P450 drug interaction. Ann Pharmacother 1998;32:761-765.
33. Metzger E, Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill. J Clin Psychopharmacol 1993;13: 128-132.
34. Suessbrich H, Schönherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Brit J Pharmacol 1997;120:968-974.
35. Giardina EG, Bigger JT, Glassman AH, Perel JM, Kantor SJ. The electrocardiographic and anfiarrhythmic effects of imipramine hydrochloride at therapeutic plasma concentrations. Circulation 1979; 60:1045-1052.
36. Lyman GH, Williams CC, Dinwoodie WR, Schocken DD. Sudden death in cancer patients receiving lithium. J Clin Oncol 1984;2: 1270-1276.
37. Knudsen K, Heath A. Effects of self poisoning with maprotiline. Br Med J (Clin Res Ed) 1984;288:601-603.
38. Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998;155:660-665.
39. Agelink MW, Majewski T, Wurthmann C, Lukas K, Ullrich H, Linka T, Klieser E. Effects of newer atypical antipsychotics on autonomic neurocardiac function: a comparison between amisulpride, olanzapine, sertindole, and clozapine. J Clin Psychopharmacol 2001;21:8-13.
40. Crumb WJ, Beasley CM, Jr., Thornton A, Breier A. Cardiac ion channel blocking profile of olanzapine and other antipsychotics. Presented at 38th Annual Meeting, American College of Neuropsychopharmacology; Acapulco, Mexico; 1999.
41. Leibowitz M, Lieberman AN, Neophytides A, Gopinathan G, Goldstein M. The effects of pergolide on the cardiovascular system of 40 patients with Parkinson's disease. Adv Neurol 1983;37:121-130.
42. Kang J, Wang L, Cai F, Rampe D. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol 2000;392:137-140.
43. Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1990;33:199-204.
44. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001;20:215-219.
45. Gajwani P, Pozuelo L, Tesar GE. QT interval prolongation associated with quetiapine (Seroquel) overdose. Psychosomatics 2000;41:63-65.
46. Ravin DS, Levenson JW. Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 1997;31:867-870.
47. Barnett AA. Safety concerns over antipsychotic drug, sertindole. Lancet 1996;348:256.
48. Rampe D, Murawsky MK, Grau J, Lewis EW. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Therapeu 1998;286:788-793.
49. Lande G, Drouin E, Gauthier C, Chevallier JC, Godin JF, Chiffoleau A, Le Marec H. Arrhythmogenic effects of sultopride chlorhydrate: clinical and cellular electrophysiological correlation. Ann Fr Anesth Reanim 1992;11:629-635.
50. Levenson JL. Prolonged QT interval after trazodone overdose. Am J Psychiatry 1999;156:969-970.
51. Mehtonen OP, Aranko K, Malkonen L, Vapaatalo H. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58-64.
52. Drolet B, Vincent F, Rail J, Chahine M, Deschenes D, Nadeau S, Khalifa M, Hamelin BA, Turgeon J. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Therapeu 1999;288:1261-1268.
53. Partridge SJ, Maclver DH, Solanki T. A depressed myocardium. J Toxicol Clin Toxicol 2000;38:453-455.
54. Liljeqvist JA, Edvardsson N. Torsade de pointes tachycardias induced by overdosage of zimeldine. J Cardiovasc Pharmacol 1989;14: 666-670.
55. Psychopharmacological Drugs Advisory Committee. Briefing document for Zeldox capsules (Ziprasidone HCl). The Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services; Rockville, MD; 19 Jul 2000. NDA-825:1-173.
56. Constantino EA, Roose SP, Woodring S. Tricyclic-induced orthostatic hypotension. Significant difference in depressed and non-depressed states. Pharmacopsychiatry 1993;26:125-127.
57. Gorman, JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety 1996;4:160-168.
58. Walsh BT. Psychopharmacologic treatment of bulimia nervosa. J Clin Psychiatry 1991;52 Suppl:34-38.
59. Daly JM, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am 1998;45:1123-1135.
60. Coupland N, Wilson S, Nutt D. Antidepressant drugs and the cardiovascular system: a comparison of tricyclics and selective serotonin reuptake inhibitors and their relevance for the treatment of psychiatric patients with cardiovascular problems. J Psychopharmacol 1997;11:83-92.
61. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994;55 Suppl A:83-87.
62. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44:273-275.
63. Glassman AH, Preud'homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993;54 Suppl:16-22.
64. Pentel PR, Benowitz NL. Tricyclic antidepressant poisoning. Management of arrhythmias. Med Toxicol 1986;1:101-121.
65. Grace AA, Camm AJ. Quinidine. N Engl J Med 1998;338:35-45.
66. Bigger JT, Giardina EG, Perel JM, Kantor SJ, Glassman AH. Cardiac antiarrhythmic effect of imipramine hydrochloride. N Engl J Med 1977;296:206-208.
67. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991,324:781-788.
68. Glassman AH, Roose SP, Bigger JT. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 1993; 269:2673-2675.
69. Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, Zucker HD. The nature and course of depression following myocardial infarcfion. Arch Intern Med 1989;149:1785-1789.
70. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994;151:979-986.
71. Roose SP, Spatz E. Depression and heart disease. Depress Anxiety 1998;7:158-165.
72. Glassman AH. Depression, cardiac death, and the central nervous system. Neuropsychobiology 1998;37:80-83.
73. Carney RM, Freedland KE, Veith RC, Jaffe AS. Can treating depression reduce mortality after an acute myocardial infarction? Psychosom Med 1999;61:666-675.
74. Hemingway H, Marmot M. Evidence based cardiology: psychosocial factors in the aetiology and prognosis of coronary heart disease. Systematic review of prospective cohort studies. Br Med J 1999;318: 1460-1467.
75. Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999;99:2192-2217.
76. Cleophas TJ. Depression and myocardial infarction. Implications for medical prognosis and options for treatment. Drugs Aging 1997;11: 111-118.
77. Roose SP, Spatz E. Treatment of depression in patients with heart disease. J Clin Psychiatry 1999;60 Suppl 20:34-37.
78. Davies MJ. Pathological view of sudden cardiac death. Br Heart J 1981;45:88-96.
79. Farb A, Tang AL, Burke AP, Sessums L, Liang Y, Virmani R. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction. Circulation 1995;92:1701-1709.
80. Thorogood M, Cowen P, Mann J, Murphy M, Vessey M. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992;340:1067-1068.
81. Lapane KL, Zierler S, Lasater TM, Barbour MM, Carleton R, Hume AL. Is the use of psychotropic drugs associated with increased risk of ischemic heart disease? Epidemiology 1995;6:376-381.
82. Pratt LA, Ford DE, Crum RM, Armenian HK, Gallo JJ, Eaton WW. Depression, psychotropic medication, and risk of myocardial infarction. Prospective data from the Baltimore ECA follow-up. Circulation 1996;94:3123-3129.
83. Weeke A, Juel K, Vaeth M. Cardiovascular death and manicdepressive psychosis. J Affect Disord 1987;13:287-292.
84. Avery D, Winokur G. Mortality in depressed patients treated with electroconvulsive therapy and antidepressants. Arch Gen Psychiatry 1976;33:1029-1037.
85. Nikolic G, Bishop RL, Singh JB. Sudden death recorded during Holter monitoring. Circulation 1982;66:218-225.
86. Malzberg B. Mortality among patients with involutional melancholia. Am J Psychiatry 1937;93:1231-1238.
87. Fuller RG. What happens to mental patients after discharge from hospital? Psychiatry Quarterly 1935;9:95-104.
88. Malizia AL, Melichar JK, Rhodes CG, Haida A, Reynolds AH,Jones T, Nutt DJ. Desipramine binding to noradrenaline reuptake sites in cardiac sympathetic neurons in man in vivo. Eur J Pharmacol 2000;391:263-267.
89. Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ, Birmaher B, Goldblatt A. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 1996;35:1491-1501.
90. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993;32:792-797.
91. Sudden death in children treated with a tricyclic antidepressant Med Lett Drugs Ther 1990;32:53.
92. Pacher P, Ungvari Z, Kecskemeti V, Furst S. Review of cardiovascular effects of fluoxetine, a selective serotonin reuptake inhibitor, compared to tricyclic antidepressants. Curr Med Chem 1998;5:381-390.
93. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-480.
94. Barbey JT, Roose SP. SSRI safety in overdose. J Clin Psychiatry 1998;59 Suppl 15:42-48.
95. Ellison JM, Milofsky JE, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990;51:385-386.
96. Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991;52:174-176.
97. Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998;279:287-291.
98. Shapiro PA, Lesperance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Sertraline Anti-Depressant Heart Attack Trial. Am Heart J 1999;137:1100-1106.
99. Ban TA, St Jean A. Electrocardiographic changes induced by phenothiazine drugs. Am Heart J 1965;70:575-576.
100. Alvarez-Mena SC, Frank MJ. Phenothiazine-induced T-wave abnormalities. Effects of overnight fasting.JAMA 1973;224:1730-1733.
101. Shader RI, Greenblatt DJ. Potassium, antipsychotic agents, arrhythmias, and sudden death. J Clin Psychopharmacol 1998;18:427-428.
102. Liberatore MA, Robinson DS. Torsade de pointes: a mechanism for sudden death associated with neuroleptic drug therapy? J Clin Psychopharmacol 1984;4:143-146.
103. Henderson RA, Lane S, Henry JA. Life-threatening ventricular arrhythmia (torsades de pointes) after haloperidol overdose. Hum Exp Toxicol 1991;10:59-62.
104. Committee on Safety of Medicines. QT interval prolongation with antipsychotics. Current Problems in Pharmacovigilance 2001;27:4.
105. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-1167.
106. Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782.
107. Czekalla J, Beasley CM, Jr., Dellva MA, Berg PH, Grundy S. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry 2001;62: 191-198.
108. Pezawas L, Quiner S, Moertl D, Tanscher J, Barnas C, Kufferle B, Wolf R, Kasper S. Efficacy, cardiac safety and tolerability of sertindole: a drug surveillance. Int Clin Psychopharmacol 2000;15:207-214.
109. Ruschena D, Mullen PE, Burgess P, Cordner SM, Barry-Walsh J, Drummer OH, Palmer S, Browne C, Wallace C. Sudden death in psychiatric patients. Br J Psychiatry 1998;172:331-336.
110. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7.:212-217.
111. Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol 2001;15:120-126.
112. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocardifis and cardiomyopathy associated with dozapine. Lancet 1999;354:1841-1845.
113. Hagg S, Spigset O, Bate A, Soderstrom TG. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001;21:382-388.
114. La Grenade L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001;345:224-225.
115. Coulter DM, Bate A, Meyboom RH, Lindquist M, Edwards IR. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. Br Med J 2001;322:1207-1209.
116. Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 2001;179:167-71.:167-171.
117. Capel MM, Colbridge MG, Henry JA. Overdose profiles of new antipsychotic agents. Int J Neuropsychopharmacol 2000;3:51-54.
118. Frangou S, Lewis M. Atypical antipsychotics in ordinary clinical practice: a pharmaco-epidemiologic survey in a south London service. Eur Psychiatry 2000;15:220-226.
119. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and pro-arrhythmia by nonanti-arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000;47:219-233.
120. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J 1993;14:3-13.
121. Priori SG, Barhanin J, Hauer RN, Haverkamp W,Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde AM. Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. Circulation 1999;99:518-528.
122. Isenberg G, Tamargo J. Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes. Eur J Pharmacol 1985;108:121-131.
123. Delpon E, Tamargo J, Sanchez-Chapula J. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol 1991;344:645-652.
124. Delpon E, Tomargo J, Sanchez-Chapula J. Effects of imipramine on the transient outward current in rabbit atrial single cells. Brit J Pharmacol 1992;106:464-469.
125. Manzanares J, Tamargo J. Electrophysiological effects of imipramine in nontreated and in imipramine-pretreated rat atrial fibres. Br J Pharmacol 1983;79:167-175.
126. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 1990;96:195-215.
127. Hancox JC, Levi AJ, Witchel HJ. Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential. Pflügers Arch 1998;436:843-853.
128. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci, U S A 1994;91:3438-3442.
129. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
130. Kr, potassium channel. Cell 1995;81:299-307.
131. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, Van Raay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Towbin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT. Positional cloning of a novel potassium channel gene: KvLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996;12: 17-23.
132. Ks cardiac potassium channel. Nature 1996;384:78-80.
133. Ks potassium channel. Nature 1996;384:80-83.
134. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
135. Wang Q, Shen J, Li Z, Timothy K, Vincent GM, Priori SG, Schwartz PJ, Keating MT. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Human Molecular Genetics 1995;4:1603-1607.
136. + channels as pharmacological targets: present and future implications. Biochem Pharmacol 1998;55:1741-1746.
137. + current activation in guinea pig ventricular myocytes. Circ Res 1994;74:687-699.
138. Lydiard RB, Gelenberg AJ. Amoxapine-an antidepressant with some neuroleptic properties? A review of its chemistry, animal pharmacology and toxicology, human pharmacology, and clinical efficacy. Pharmacotherapy 1981;1:163-178.
139. Kinugawa T, Kotake H, Mashiba H. Inhibitory actions of amoxapine, a tricyclic antidepressant agent, on electrophysiological properties of mammalian isolated cardiac preparations. Br J Pharmacol 1988;94: 1250-1256.
140. + current (I(to)) by antidepressant drugs. J Cardiovasc Pharmacol 1998;32:527-534.
141. Litovsky SH, Antzelevitch C. Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res 1988;62:116-126.
142. Liu DW, Gintant GA, Antzelevitch C. Ionic bases for electrophysiological distinctions among epicardial, midmyocardial, and endocardial myocytes from the free wall of the canine left ventricle. Circ Res 1993;72:671-687.
143. Guo W, Li H, London B, Nerbonne JM. Functional consequences of elimination of i(to,f) and i(to,s): early afterdepolarizations, atrioventricular block, and ventricular arrhythmias in mice lacking Kvl.4 and expressing a dominant-negative Kv4 alpha subunit. Circ Res 2000;87:73-79.
144. Shibata EF, Drury T, Refsum H, Aldrete V, Giles W. Contributions of a transient outward current to repolarization in human atrium. Am J Physiol 1989;257:H1773-H1781.
145. Josephson IR, Sanchez-Chapula J, Brown AM. Early outward current in rat single ventricular cells. Circ Res 1984;54:157-162.
146. + current in human ventricular myocytes. Circ Res 1996;78:689-696.
147. Antzelevitch C, Sicouri S, Litovsky SH, Lukas A, Krishnan SC, Di Diego JM, Gintant GA, Liu DW. Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991;69:1427-1449.
148. 2+ channel blocker in heart. Mol Pharmacol 1990;37:752-757.
149. Ogata N, Narahashi T. Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Brit J Pharmacol 1989;97:905-913.
150. Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996;94:1018-1022.
151. Choy AM, Lang CC, Chomsky DM, Rayos GH, Wilson JR, Roden DM. Normalization of acquired QT prolongation in humans by intravenous potassium. Circulation 1997;96:2149-2154.
152. Hancox JC, Witchel HJ. Psychotropic drugs, HERG, and the heart. Lancet 2000;356:428.
153. Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol 1998;18:477-481.
154. Nguyen PT, Scheinman MM, Seger J. Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. Circulation 1986;74:340-349.
155. Thomas M, Maconochie JG, Fletcher E. The dilemma of the prolonged QT interval in early drug studies. Br J Clin Pharmacol 1996;41:77-81.
156. Schwartz PJ, Locati E. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy. Eur Heart J 1985;6 Suppl D: 103-114.
157. Rubart M, Pressler ML, Pride HP, Zipes DP. Electrophysiological mechanisms in a canine model of erythromycin-associated long QT syndrome. Circulation 1993;88:1832-1844.
158. Moss AJ, Schwartz PJ, Crampton RS, Tzivoni D, Locati E, MacCluer J, Hall W, Weitkamp L, Vincent G, Garson AJ, Robinson J, Benhorin J, Choi S. The long QT syndrome: prospective longitudinal study of 328 families. Circulation 1991;84:1136-1144.
159. Priori SG, Napolitano C, Schwartz PJ. Low penetrance in the long-QT syndrome: clinical impact. Circulation 1999;99:529-533.
160. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-1633.
161. Zipes DP. Sympathetic stimulation and arrhythmias. N Engl J Med 1991;325:656-657.
162. Meredith IT, Broughton A,Jennings GL, Esler MD. Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 1991;325:618-624.
163. Podrid PJ, Fuchs T, Candinas R. Role of the sympathetic nervous system in the genesis of ventricular arrhythmia. Circulation 1990; 82:1103-1113.
164. Veith RC, Lewis N, Linares OA, Barnes RF, Raskind MA, Villacres EC, Murburg MM, Ashleigh EA, Castillo S, Peskind ER. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994;51:411-422.
165. Breier A, Wolkowitz OM, Roy A, Potter WZ, Pickar D. Plasma norepinephrine in chronic schizophrenia. Am J Psychiatry 1990;147: 1467-1470.
166. Castellani S, Ziegler MG, van Kammen DP, Alexander PE, Siris SG, Lake CR. Plasma norepinephrine and dopamine-beta-hydroxylase activity in schizophrenia. Arch Gen Psychiatry 1982;39:1145-1149.
167. Walsh BT, Giardina EG, Sloan RP, Greenhill L, Goldfein J. Effects of desipramine on autonomic control of the heart. J Am Acad Child Adolesc Psychiatry 1994;33:191-197.
168. Levy MN, Blattberg B. The influence of cocaine and desipramine on the cardiac responses to exogenous and endogenous norepinephrine. Eur J Pharmacol 1978;48:37-49.
169. Baum T, Shropshire AT. Inhibition of efferent sympathetic nerve activity by 5-hydroxytryptophan and centrally administered 5-hydroxytryptamine. Neuropharmacology 1975;14:227-233.
170. Lehnert H, Lombardi F, Raeder EA, Lorenzo AV, Verrier RL, Lown B, Wurtman RJ. Increased release of brain serotonin reduces vulnerability to ventricular fibrillation in the cat. J Cardiovasc Pharmacol 1987;10:389-397.
171. Rabinowitz SH, Lown B. Central neurochemical factors related to serotonin metabolism and cardiac ventricular vulnerability for repetitive electrical activity. Am J Cardiol 1978;41:516-522.
172. Marais GE, Verrier RL, Lown B. Mechanisms mediating the protective effects of central serotonergic agonists on vulnerability to ventricular fibrillation in the normal and ischemic heart. Circulation 1981;64:IV320.
173. Verrier RL, Lown B. Behavioral stress and cardiac arrhythmias. Annu Rev Physiol 1984;46:155-176.
174. Brum G, Osterrieder W, Trautwein W. Beta-adrenergic increase in the calcium conductance of cardiac myocytes studied with the patch clamp. Pflügers Arch 1984;401:111-118.
175. Perchenet L, Hinde AK, Patel KC, Hancox JC, Levi AJ. Stimulation of Na/Ca exchange by the beta-adrenergic/protein kinase A pathway in guinea-pig ventricular myocytes at 37 degrees C. Pflügers Arch 2000;439:822-828.
176. Janiak R, Lewartowski B. Early after-depolarizations induced by noradrenaline may be initiated by calcium released from sarcoplasmic reticulum. Mol Cell Biochem 1996;163/164:125-130.
177. Volders PG, Vos MA, Szabo B, Sipido KR, de Groot SH, Gorgels AP, Wellens HJ, Lazzara R. Progress in the understanding of cardiac early afterdepolarizations and torsades de pointes: time to revise current concepts. Cardiovasc Res 2000;46:376-392.
178. 2+ currents in single atrial myocytes. Am J Physiol 1990;259: H1842-H1850.
179. Arsenian MA. Magnesium and cardiovascular disease. Prog Cardiovasc Dis 1993;35:271-310.
180. Bril A, Forest MC, Cheval B, Faivre JF. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. Cardiovasc Res 1998;37:130-140.
181. Patterson E, Scherlag BJ, Szabo B, Lazzara R. Facilitation of epinephrine-induced afterdepolarizations by class III antiarrhythmic drugs. J Electrocardiol 1997,30:217-224.
182. Priori SG, Corr PB. Mechanisms underlying early and delayed afterdepolarizations induced by catecholamines. Am J Physiol 1990; 258:H1796-H1805.
183. Millar WM. Deaths after overdoses of orphenadrine. Lancet 1977; 2:566.
184. Clarke B, Mair J, Rudolf M. Acute poisoning with orphenadrine. Lancet 1985;1:1386.
185. Loga S, Curry S, Lader M. Interactions of orphenadrine and phenobarbitone with chlorpromazine: plasma concentrations and effects in man. Br J Clin Pharmacol 1975;2:197-208.
186. Vanoli E, De Ferrari GM, Stramba-Badiale M, Hull SS, Jr., Foreman RD, Schwartz PJ. Vagal stimulation and prevention of sudden death in conscious dogs with a healed myocardial infarction. Circ Res 1991;68:1471-1481.
187. De Ferrari GM, Vanoli E, Stramba-Badiale M, Hull SS, Jr., Foreman RD, Schwartz PJ. Vagal reflexes and survival during acute myocardial ischemia in conscious dogs with healed myocardial infarction. Am J Physiol 1991;261:H63-H69.
188. Levy MN, Zieske H. Autonomic control of cardiac pacemaker activity and atrioventricular transmission. J Appl Physiol 1969;27:465-470.
189. Stramba-Badiale M, Vanoli E, De Ferrari GM, Cerati D, Foreman RD, Schwartz PJ. Sympathetic-parasympathetic interaction and accentuated antagonism in conscious dogs. Am J Physiol 1991;260: H335-H340.
190. Kovacs RJ, Bailey JC. Effects of acetylcholine on action potential characteristics of atrial and ventricular myocardium after bilateral cervical vagotomy in the cat. Circ Res 1985;56:613-620.
191. Boyett MR, Kirby MS, Orchard CH, Roberts A. The negative inotropic effect of acetylcholine on ferret ventricular myocardium. J Physiol 1988;404:613-635.
192. Hancox JC, Levi AJ, Brooksby P. Intracellular calcium transients recorded with Fura-2 in spontaneously active myocytes isolated from the atrioventricular node of the rabbit heart. Proc R Soc Lond B Biol Sci 1994;255:99-105.
193. Chevalier P, Ruffy F, Danilo PJ, Rosen MR. Interaction between alpha-1 adrenergic and vagal effects on cardiac rate and repolarization. J Pharmacol Exp Ther 1998;284:832-837.
194. Zaza A, Malfatto G, Schwartz PJ. Sympathetic modulation of the relation between ventricular repolarization and cycle length. Circ Res 1991;68:1191-1203.
195. Middleton HC, Nutt DJ. Heart rate response to standing as an index of adaptation to imipramine during treatment of panic disorder. Human Psychopharmacology 1988;3:191-194.
196. Committee on Safety of Medicines. Fluvoxamine and fluoxetine-interaction with monoamine oxidase inhibitors, lithium and tryptophan. Current Problems 1989;26.
197. Brannan SK, Talley BJ, Bowden CL. Sertraline and isocarboxazid cause a serotonin syndrome. J Clin Psychopharmacol 1994;14:144-145.
198. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Drug interactions with newer antidepressants: role of human cytochromes P450. J Clin Psychiatry 1998;59 Suppl 15:19-27.
199. Strain JJ, Caliendo G, Alexis JD, Lowe RS, Karim A, Loigman M. Cardiac drug and psychotropic drug interactions: significance and recommendations. Gen Hosp Psychiatry 1999;21:408-429.
200. Strain JJ, Caliendo G, Himelein D. Part II: Drug-psychotropic drug interactions and end organ dysfunction: clinical management recommendations, selected bibliography, and updating strategies. Gen Hosp Psychiatry 1996;18:294-375.
201. Darragh A, Kenny M, Lambe R, Brick I. Sudden death of a volunteer. Lancet 1985;1:93-94.
202. Flockhart DA, Drici MD, Kerbusch T, Soukhova N, Richard E, Pearle PL, Mahal SK, Babb VJ. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol 2000;20:317-324.
203. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984;35:503-511.
204. Idle JR. The heart of psychotropic drug therapy. Lancet 2000;355: 1824-1825.
205. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:48-57.
206. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-122.
207. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br J Psychiatry 1995;167:575-580.
208. Shin JG, Kane K, Flockhart DA. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol. Br J Clin Pharmacol 2001;51:81-86.
209. Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999;19:23S-35S.
210. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29 Suppl 1:33-44.
211. Preskorn SH, Alderman J, Chung M, Harrison W, Messig M, Harris S. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98.
212. Harvey AT, Preskorn SH. Interactions of serotonin reuptake inhibitors with tricyclic antidepressants. Arch Gen Psychiatry 1995; 52:783-785.
213. Shen WW. The metabolism of atypical antipsychotic drugs: an update. Ann Clin Psychiatry 1999;11:145-158.
214. Westermeyer J. Fluoxetine-induced tricyclic toxicity: extent and duration. J Clin Pharmacol 1991;31:388-392.
215. Walley T, Pirmohamed M, Proudlove C, Maxwell D. Interaction of metoprolol and fluoxetine. Lancet 1993;341:967-968.
216. Lin K, Poland RE. Ethnicity, culture, and psychopharmacology. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: the fourth generation of progress. New York: Raven Press, 1995:1907-17.
217. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000;68:401-411.
218. Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 1989;45:28-33.
219. Katz MR. Raised serum levels of desipramine with the antiarrhythmic propafenone. J Clin Psychiatry 1991;52:432-433.
220. von Bahr C, Movin G, Nordin C, Liden A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjoqvist F. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991;49:234-240.
221. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-1214.
222. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986;32:313-334.
223. Thomson AH, McGovern EM, Bennie P, Caldwell C, Smith P. Interaction between fluvoxamine and theophylline. Pharmaceut J 1992;1:137.
224. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423.
225. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-584.
226. Greenblatt DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52:479-486.
227. von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 1996;36:783-791.
228. Sternbach H. Fluoxetine-associated potentiation of calcium-channel blockers. J Clin Psychopharmacol 1991;11:390-391.
229. Swims MP. Potential terfenadine-fluoxetine interaction. Ann Pharmacother 1993;27:1404-1405.
230. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-112.
231. Gram L, Resiby N, Ibsen I, Nagy A, Dencker SJ, Bech P, Petersen GO, Christiansen J. Plasma levels and antidepressive effect of imipramine. Clin Pharmacol Ther 1976;19:318-324.
232. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand Suppl 1989;350:102-106.
233. Bergstrom RF, Lemberger L, Farid NA, Wolen RL. Clinical pharmacology and pharmacokinetics of fluoxetine: a review. Br J Psychiatry 1988;153 suppl. 3:47-50.
234. Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32 Suppl 1:37-42.
235. Woolfrey S, Gammack NS, Dewar MS, Brown PJ. Fluoxetine-warfarin interaction. Br Med J 1993;307:241.
236. + channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharm 1998;54:113-121.
237. Stahl SM. Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59 Suppl 4:5-14.